在日本,新辅助化疗(CF方案)加手术是二期和三期食管癌的标准推荐。但西方对于局部进展期可切除食管癌的治疗推荐是新辅助放化疗加手术。长期以来,食管癌的最佳新辅助模式存在很大争议。
日本一项“随机比较术前新辅助顺铂联合氟脲嘧啶(CF)、多西紫杉醇联合顺铂和氟脲嘧啶化疗(DCF)和术前新辅助顺铂联合氟脲嘧啶化疗同期放疗(CF—RT)对可手术ESCC的Ⅲ期临床研究”(JCOG1109)已经得到生存结果。
同步放化疗、DCF三联化疗分别与传统经典CF两药新辅助相比,DCF胜出。未来DCF有望成为食管鳞癌的新辅助治疗推荐模式。
![](/wp-content/uploads/2022/03/60d81b43a3c80a042b4e213ae84dff9b.png)
![](/wp-content/uploads/2022/03/767e1405d54662fc980dc449b95196cb.png)
![](/wp-content/uploads/2022/03/31d1fa8c24da05e9cfdcbbe2c1ac0029.png)
![](/wp-content/uploads/2022/03/3f1e4d00ea06c8657bcc7323690e4ee6.png)
![](/wp-content/uploads/2022/03/2291df0ca59627393701c574aa0e04f6.png)
![](/wp-content/uploads/2022/03/1ea46bfd2a4898f94aacc72630f17fef.png)
![](/wp-content/uploads/2022/03/2dfd6a2a5cabece3527bd5975a11a1e7.png)
![](/wp-content/uploads/2022/03/005dc938621ffb4a4ed256c468feb907.png)
![](/wp-content/uploads/2022/03/6d7eff56510c2fe6ffd926fb99254d46.png)
![](/wp-content/uploads/2022/03/f325a600d47a4f2c3c078801335ded76.png)
![](/wp-content/uploads/2022/03/2fe0a814e2dc220339d18957500a9172.png)
![](/wp-content/uploads/2022/03/433d82be0c0c533e0f7262b8ac56381b.png)
![](/wp-content/uploads/2022/03/b39a6ca97fd9992f1aeb2028a4d2f574.png)
![](/wp-content/uploads/2022/03/b032da69b40cc8daf42a5689d6655ea0.png)
![](/wp-content/uploads/2022/03/3699d8fcae1ad037e74ab571aa85ba92.png)
![](/wp-content/uploads/2022/03/96d27828870d4978f27ab70c806ccf9a.png)
![](/wp-content/uploads/2022/03/b20006fb7f6270c274856ff598313c54.png)
![](/wp-content/uploads/2022/03/243a8a1f10698744492a8f2d33b922fe.png)
本文由 luchaojing发布,仅供学习交流,如有侵权,请联系删除,谢谢。
原文链接:http://www.xxwk.net/archives/1002
原文链接:http://www.xxwk.net/archives/1002